Regulators require cannabis derived investigational drugs to be controlled for identity, quality, purity, potency and consistency. Every one of those five words is a manufacturing and documentation requirement, which is why reliable cultivation, extraction and analytical work matters more than branding.
The platform, not the product
A stronger proposition is a standardised investigational product platform. Delta 9 THC API, a defined formulation, a fixed dose, a batch specific Certificate of Analysis and stability data, released as clinical trial material. The same platform can carry several formulations without changing the underlying discipline.
Where to start on indications
A new clinical trial supplier should not claim dozens of indications. We focus first on cancer supportive care and chemotherapy induced nausea and vomiting, neuropathic pain, multiple sclerosis spasticity and palliative medicine. Those are the areas with the strongest human evidence and established cannabinoid medicines already in use.
Exploratory opportunity exists in PTSD and anxiety, sleep disorders, inflammatory conditions, opioid sparing pain management and selected neurological conditions. The evidence and development risk vary considerably, so we treat those as research supply rather than a commercial promise.
What the sponsor still has to hold
For drug development in the United States, for example, a sponsor generally needs an investigational new drug application, adequate chemistry, manufacturing and controls information characterising the product, clinical protocols, appropriate manufacturing controls, and additional controlled substance requirements where the material is scheduled. Our job is to make the supply side of that file complete and defensible.
See the indications we support